Shots:
Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers
Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma
The study reveals that four out of the ten patients received only…
Shots:
There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States
Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity
Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…

